



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

**Summary of Main Points from the Meeting held on Monday 8<sup>th</sup> October 2018**

**2. Minutes and Summary Notes from last meeting**

The Minutes and Summary notes from the 10<sup>th</sup> September 2018 Medicines Group meeting were approved and will be circulated.

**3. Matters Arising**

The Group noted the matters arising from the previous meeting.

**4. Business to be transacted by the Medicines Group**

**4.1 Formulary Applications**

***Full Applications***

• **Dalbavancin 500mg powder for concentrate for solution for infusion (Xydalba<sup>®</sup>)**

Requested by antimicrobial stewardship group. Xydalba<sup>®</sup> is a bactericidal lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. The request is also to be used for treatment of deep-seated Gram-positive infections which is outside the product licence. Xydalba<sup>®</sup> will only be prescribed on the advice of a microbiology consultant for patients requiring prolonged intravenous (IV) antibiotic treatment and eligible for discharge but not suitable for daily administration of IV antibiotic treatment as an outpatient/in the community.

**Decision: Approved for addition to the formulary**

• **Cefepime 2g solution for injection/infusion (Renapime<sup>®</sup>)**

Requested by Microbiology Department be used as a second line treatment option when first line anti-pseudomonal therapies are unsuitable due to resistance/allergies (1<sup>st</sup> line therapies include Ceftazidime, Piperacillin/Tazobactam, Meropenem, Aminoglycosides or Ciprofloxacin).

Having Cefepime available will provide a further treatment option before the last-line anti-pseudomonal therapies (Ceftazidime-avibactam or ceftaroline-tazobactam) are used.

Only to be used on the recommendation of the Microbiology Department.

**Decision: Approved for addition to the formulary**

***Ex-panel***

• **BCG Vaccine**

A new UK-licensed BCG vaccine manufactured by AJ Vaccines (formerly the Statens Serum Institut (SSI)) is now available.

BCG vaccine is centrally supplied by PHE to the NHS in line with national policy to selectively offer vaccination to those at increased risk of exposure to tuberculosis infection but a licensed version has been unavailable since 2015.

**Decision: Approved for addition to the formulary**

• **Hydrocortisone 0.5mg, 1mg and 2mg Granules (Alkindi<sup>®</sup>)**

Currently we use Hydrocortisone 10mg tablets, crush and disperse them in water before administering an aliquot to small children.

Since September 2018, a new formulation of Hydrocortisone (Alkindi<sup>®</sup>) has become available. These granules (in capsules for opening) are available in 0.5mg, 1mg & 2mg and are licenced for use in children (from birth - <18years).

There are currently 12 patients being treated who could receive Alkindi<sup>®</sup> granules. This will cost ~12K/yr. (vs. ~£1.4k if using 10mg Hydrocortisone tablets). The Paediatric Managers (Dr Kingi Aminu, Mel Guinan and Nicola Sprigens) have been made aware of the cost implication for the Paediatric Directorate.

**Decision: Approved for addition to the formulary**

• **Follitropin Alpha (Bemfola<sup>®</sup>) pre-filled pen (75unit, 150unit, 225unit, 300unit and 450unit)**

Requested by Assisted Conception Unit for replace pre-filled syringes. Negligible cost difference between the different formulations of the same strength preparations. Easier for patient to self-administer.

**Decision: Approved for addition to the formulary**



## Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

### **Removals**

- Nil

### **NICE Approved drug applications**

**Alectinib for untreated ALK-positive advanced non-small-cell lung cancer in line with NICE TA536**

Approved by NICE in August 2018

**Decision: Approved for addition to the formulary**

### **Pharmacoeconomic Board requests**

**IVIg for Autoimmune Encephalitis**

Approved by the Pharmacoeconomic Board on 16/09/18

For noting by the Group.

**Decision: Noted**

### **4.2 Trust Medicines Policy**

#### **• TMP - Section 7: Controlled Drugs**

Following a specific scenario - Section 6.14 (Illicit Substance Use) updated to include:

- Obtaining patient consent to destroy patient's own supply of illicit substances
- Use of Telephone Line 101 to contact the Metropolitan Police.

The Trust allowable limited for CD liquid discrepancies were also clarified as being up to 5ml for bottles under 100ml in volume and up to 10ml for bottles greater than 100ml in volume and that these limits are per bottle and so can be doubled or tripled for 2 or 3 bottles respectively. Policy will be updated to reflect this.

**Decision: Approved**

#### **• TMP - Section 1: Introduction**

Updated to include the Immunoglobulin Approval Panel and the Pharmacoeconomic Board as two of the groups that report to the Trust Medicines Group. This section was also updated to reflect the merger of the Local Chemotherapy Group (CWH) and the Clinical Chemotherapy Service Group (WMUH).

**Decision: Approved**

### **4.3 Medicines Optimisation**

#### **• Impact on Brexit on medicine supply at Chelsea & Westminster Hospital NHS Foundation Trust**

Report that summarises that impact of Brexit on medicine supply at Chelsea & Westminster Hospital NHS Foundation Trust.

Enclosures include:

- Summary e-mail
- Letter from Department of Health
- Report

**Decision: Noted**

#### **• Immunoglobulin Implementation Plan**

Report that summarises the plan for managing the supply of Immunoglobulin within the NHS

Enclosures include:

- Letter from NHS England 1
- Letter from NHS England 2
- London Update and Implementation Plan

**Decision: Noted**

### **4.4 NICE Technical Appraisals and Guidance**

#### **a) NICE Technical Appraisals**



**Chelsea and Westminster Hospital NHS Foundation Trust  
Trust Medicines Group**

**2 Appraisals published in September 2018**

**TA540 – Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma**

**Formulary status / Action**

**Currently included on the formulary for another indication.**

**To confirm numbers likely to treat at both hospital sites**

**TA541 – Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia**

**Formulary status / Action**

**Nil action - Not applicable - Condition not treated at CWFT**

**b) NICE Highly Specialised Technologies**

**7 Highly Specialised Technologies published since January 2015**

**HST1 – Eculizumab for treating atypical haemolytic uraemic syndrome**

**Formulary status / Action**

**Nil action - Not applicable - Condition not treated at CWFT**

**HST2 – Elosulfase alfa for treating mucopolysaccharidosis type IVa**

**Formulary status / Action**

**Nil action - Not applicable - Condition not treated at CWFT**

**HST3 – Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene**

**Formulary status / Action**

**Nil action - Not applicable - Condition not treated at CWFT**

**HST4 – Migalastat for treating Fabry disease**

**Formulary status / Action**

**Nil action - Not applicable - Condition not treated at CWFT**

**HST5 – Eliglustat for treating type 1 Gaucher disease**

**Formulary status / Action**

**Nil action - Not applicable - Condition not treated at CWFT**

**HST6 – Asfotase alfa for treating paediatric-onset hypophosphatasia**

**Formulary status / Action**

**Nil action - Not applicable - Condition not treated at CWFT**

**HST7 – Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency**

**Formulary status / Action**

**Nil action - Not applicable - Condition not treated at CWFT**

**4.5 IVIG requests**

**CWH Site**

- IVIG issues for September 2018 - CW site

There were 8 IVIG issues in July 2018, with 8 new requests

**WMUH Site**

- IVIG issues for August 2018 - WMUH site

There were 15 IVIG issues in August 2018, with 3 new requests



## Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

- IVIG issues for September 2018 - WMUH site  
There were 16 IVIG issues in September 2018, with 3 new requests  
**Decision: Approved**

**Immunoglobulin Approval Panel - Terms of Reference**  
Terms of reference for the Immunoglobulin Approval Panel  
**Decision: Approved**

### 4.6 Items for noting

- **Medication Safety Bulletin - Insulin**  
Medication Safety Bulletin relating to Insulin  
**Decision: Noted**

- **MHRA Drug Safety Update - September 2018**  
MHRA update for September 2018  
**Decision: Noted**

### 4.7 Meeting minutes for noting

- **Homecare medicines Group meeting - September 2018**  
Minutes from Homecare medicines Group Meeting - September 2018  
**Decision: Noted**
- **Antimicrobial Steering Group Meeting - September 2018**  
Minutes from Antimicrobial Steering Group Meeting - September 2018  
**Decision: Noted**
- **HIV/GUM Directorate - Medicines Sub-Group Meeting - June 2018**  
Minutes from HIV/GUM Directorate - Medicines Sub-Group Meeting - June 2018  
**Decision: Noted**
- **HIV/GUM Directorate - Medicines Sub-Group Meeting - July 2018**  
Minutes from HIV/GUM Directorate - Medicines Sub-Group Meeting - July 2018  
**Decision: Noted**
- **HIV/GUM Directorate - Medicines Sub-Group Meeting - August 2018**  
Minutes from HIV/GUM Directorate - Medicines Sub-Group Meeting - August 2018  
**Decision: Noted**

### 4.8 Additional papers to go to Trust patient Safety Group

Nil

### 5. Any other business

Nil

### 6. Date of next meeting

**Date: Monday 12<sup>th</sup> November 2018**

**Time: 8am-9am**

**Location: Board Room (CWH Site) and Meeting Room A (WMUH Site via video conferencing)**

**Closing date: 19<sup>th</sup> October 2018**